# An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

> **NCT01340443** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 314 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01340443
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-19
- **Primary completion:** 2016-07-15
- **Final completion:** 2016-07-15
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01340443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01340443, "An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01340443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*